Skip to main content
Matthew Barth, MD, Pediatric Hematology & Oncology, Buffalo, NY, John R Oishei Children's Hospital

MatthewBarthMD

Pediatric Hematology & Oncology Buffalo, NY

Pediatric Hematologic Oncology, Pediatric Neuro-Oncology

Clinical Associate Professor, Jacobs School of Medicine and Biomedical Sciences at University at Buffalo Pediatric Transplant and Cellular Therapy Co-Director of Pediatric Neuro-Oncology Director of Pediatric Neurofibromatosis Program

Dr. Barth is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Barth's full profile

Already have an account?

Summary

  • Dr. Matthew Barth is a pediatric hematologist/oncologist in Buffalo, NY and is affiliated with John R Oishei Children's Hospital and Roswell Park Comprehensive Cancer Center. He received his medical degree from SUNY Upstate Medical University and has been in practice 12 years. He is experienced in lymphoma, personalized medicine, leukemia, stem cell transplant, cellular therapy and neuro oncology.

Education & Training

  • University at Buffalo
    University at BuffaloFellowship, Pediatric Hematology/Oncology, 2008 - 2011
  • University at Buffalo
    University at BuffaloResidency, Pediatrics, 2005 - 2008
  • SUNY Upstate Medical University
    SUNY Upstate Medical UniversityClass of 2005

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2008 - 2025
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • Young Investigator Award International Society of Paediatric Oncology, 2016
  • Henry C. and Bertha H. Buswell Fellowship University at Buffalo, 2011-2014
  • Travel Award 11th International Conference on Malignant Lymphoma, 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Matthew J. Barth, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma
    Matthew J. Barth, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • NCCN Guidelines Highlight ‘Complicated’ Treatment for Pediatric Lymphomas
    NCCN Guidelines Highlight ‘Complicated’ Treatment for Pediatric LymphomasJanuary 14th, 2020

Grant Support

  • Scholar AwardSt. Baldrick's Foundation2013–2018

Professional Memberships

Hospital Affiliations